Morgan Stanley upgraded Bausch + Lomb (BLCO) to Overweight from Equal Weight with a price target of $21, up from $14.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb to Engage at Citi Global Healthcare Conference
- Bausch + Lomb price target raised to $19 from $17 at RBC Capital
- Cautious Hold Rating on Bausch + Lomb: Awaiting Catalysts for Stock Valuation Boost
- Cautious Outlook on Bausch + Lomb: Sell Rating Amid Optimistic Projections and Execution Risks
- Bausch + Lomb Unveils Strategic Growth Plan at Investor Day